GlassScriptPhysician profile
Adrienne Hester
NPI 1366676991
$9,093.11
in general payments reported to CMS, 2019-2025
52 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,510 · 2020: $79.97 · 2021: $271 · 2022: $844 · 2023: $1,460 · 2024: $1,819 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.16 | 2019-2025 | |
| Novo Nordisk INC | $650.75 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $645.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $631.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $597.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.52 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $452.43 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $427.45 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Corcept Therapeutics | $378.02 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $323.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $270.10 | 2019-2025 | |
| Daiichi Sankyo INC. | $215.56 | 2023-2025 | Injectafer |
| Amarin Pharma, INC. | $213.08 | 2019-2023 | |
| Allergan, INC. | $212.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.79 | 2021-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.